Recruiting

SSM Predicts Outcomes of CLD Inpatients With Acute Liver Injury

In this study, a single non-invasive tool, spleen stiffness measurement (SSM), was used to monitor the disease regression of inpatients with chronic liver disease (CLD) and acute liver injury. The present study aimed to establish an early diagnosis warning model for acute-on-chronic liver failure (ACLF) by SSM and investigate the effect of dynamic changes in SSM on the short-term prognosis (28-day, 90-day morbidity and mortality) of inpatients with CLD and acute liver injury.

ClinicalTrials.gov IDNCT06173947

PhaseNot Applicable

Enrollment411

SponsorNanfang Hospital, Southern Medical University

Age18 Years

SexALL

I'm interested View official listing

Conditions studied

End Stage Liver Disease, Jaundice, Liver Dysfunction, Portal Hypertension

About this study

Interventions

Device: FibroScan® Expert 630 — The SSM by FibroScan 630 was first performed after admission, repeated at the day 5±2 as soon as feasible, and finally evaluated before discharge.

Primary outcomes

90-day transplant-free mortality (Day 90)

Eligibility information

Inclusion Criteria: 1. Age between 18 years and 80 years 2. Chronic liver diseases regardless of etiology 3. Acute liver injury with total bilirubin ≥ 3 mg/dl regardless of inducement Exclusion Criteria: 1. Prior surgery of liver diseases before enrollment such as liver transplantation, transjugular intrahepatic portosystemic shunt (TIPS), splenectomy and partial splenic embolization 2. Severe extrahepatic diseases such as chronic obstructive pulmonary disease level IV, chronic kidney disease with end-stage renal failure, myocardial infarction within 3 months before admission 3. Receiving Immunosuppressive drugs for reasons rather than chronic liver diseases 4. Diagnosis of hepatocellular carcinoma or other non-liver malignancies during screening period 5. Serious mental illnesses such as anxiety, depressive disorders to obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) 6. The pregnant 7. Jaundice due to biliary obstruction or cholestasis 8. Unsuitable to participate in this study judging by investigators

Study locations

Hepatology Unit, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515 China

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.